Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers

Phytotherapy Research

Volumn 30, Issue 3, 2016, Pages 463-468

  Bedada, Satish Kumar ^a   Neerati, Prasad ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

chlorzoxazone; CYP2E1 enzyme; hepatotoxicity; pharmacokinetics; resveratrol

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 2E1; RESVERATROL; ENZYME INHIBITOR; PLANT EXTRACT; STILBENE DERIVATIVE;

ADULT; APPARENT ORAL CLEARANCE; APPARENT VOLUME OF DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; CLINICAL TRIAL; DIET RESTRICTION; HALF LIFE TIME; HERB DRUG INTERACTION; METABOLISM; YOUNG ADULT;

ADULT; AREA UNDER CURVE; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2E1; ENZYME INHIBITORS; FASTING; HALF-LIFE; HEALTHY VOLUNTEERS; HERB-DRUG INTERACTIONS; HUMANS; MALE; PLANT EXTRACTS; STILBENES; YOUNG ADULT;

EID: 84959554492     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5549     Document Type: Article

References (34)

1. Bertelli AA, Giovannini L, Stradi R, et al,. 1996. Kinetics of trans- and cis-resveratrol (3, 4′, 5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res 16: 77-81.
2. Bishayee A, Dhir N,. 2009. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 179: 131-144.
3. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, Carroll RT,. 2010. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res 3: 753-763.
4. Brisdelli F, D'Andrea G, Bozzi A,. 2009. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10: 530-546.
5. Court MH, Von Moltke LL, Shader RI, Greenblatt DJ,. 1997. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18: 213-226.
6. Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT,. 1983. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 72: 991-994.
7. Eap CB, Schnyder C, Besson J, Savary L, Buclin T,. 1998. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin Pharmacol Ther 64: 52-57.
8. Ernstgard L, Warholm M, Johanson G,. 2004. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol 58: 190-200.
9. Frye RF, Branch RA,. 2002. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol 53: 155-1562.
10. Ioannides C,. 2003. Drug-phytochemical interactions. Inflammopharmacology 11: 7-42.
11. Jang M, Cai L, Udeani GO, et al,. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
12. Kalantari H, Das DK,. 2010. Physiological effects of resveratrol. Biofactors 36: 401-406.
13. Koop DR,. 1992. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 6: 724-730.
14. Lieber CS,. 1990. Mechanism of ethanol induced hepatic injury. Pharmacol Ther 46: 1-41.
15. Loizou GD, Cocker J,. 2001. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol 20: 321-327.
16. Lucas D, Ferrara R, Gonzalez E, et al,. 1999. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9: 377-388.
17. McCarty MF,. 2001. Inhibition of CYP2E1 with natural agents may be a feasible strategy for minimizing the hepatotoxicity of ethanol. Med Hypotheses 56: 8-11.
18. Mikstacka R, Gnojkowski J, Baer-Dubowska W,. 2002. Effect of natural phenols on the catalytic activity of cytochrome P450 2E1. Acta Biochim Pol 49: 917-925.
19. Mikstacka R, Rimando AM, Szalaty K, Stasik K, Baer-Dubowska W,. 2006. Effect of natural analogues of trans-resveratrol on cytochromes P4501A2 and 2E1 catalytic activities. Xenobiotica 36: 269-285.
20. Patel KR, Andreadi C, Britton RG, et al,. 2013. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med 5: 205ra133.
21. Peter R, Böcker R, Beaune PH, et al,. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3: 566-573.
22. Piver B, Berthou F, Dreano Y, Lucas D,. 2001. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 125: 83-91.
23. Piver B, Berthou F, Dreano Y, Lucas D,. 2003. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 73: 1199-1213.
24. Rajasekaran D, Elavarasan J, Sivalingam M, et al,. 2011. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol Med Rep 4: 1211-1217.
25. Rajnarayana K, Mada SR, Vidyasagar J, Kishore P, Krishna DR,. 2002. Validated HPLC method for determination of chlorzoxazone in human serum and its application in a clinical pharmacokinetic study. Pharmazie 57: 811-813.
26. Rajnarayana K, Venkatesham A, Nagulu M, Srinivas M, Krishna DR,. 2008. Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers. Drug Metabol Drug Interact 23: 311-321.
27. Romano B, Pagano E, Montanaro V, et al,. 2013. Novel insights into the pharmacology of flavonoids. Phytother Res 27: 1588-1596.
28. Soleas GJ, Diamandis EP, Goldberg DM,. 1997. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30: 91-113.
29. Thummel KE, Kharasch ED, Podoll T, Kunze K,. 1993. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 21: 350-357.
30. Upadhyay G, Singh AK, Kumar A, Prakash O, Singh MP,. 2008. Resveratrol modulates pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Eur J Pharmacol 596: 146-152.
31. Walle T,. 2011. Bioavailability of resveratrol. Ann N Y Acad Sci 1215: 9-15.
32. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK,. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
33. Wu X, Li C, Xing G, Qi X, Ren J,. 2013. Resveratrol downregulates Cyp2e1 and attenuates chemically induced hepatocarcinogenesis in SD rats. J Toxicol Pathol 26: 385-392.
34. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T,. 1992. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794.